An interventional study of Ultrasound Guided Intercostobrachial Nerve Block and Ultrasound Guided Erector Spinae Plane Block at T2 level in ESRD (End Stage Renal Disease), sponsored by Fatma Hatem Mokhtar. Completed at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Fatma Hatem Mokhtar · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Renal Insufficiency, Chronic with a site in Egypt — 23 open to participants now, 28 under way, 4 of them phase 3. Renal Insufficiency, Chronic · Egypt.
Among the 64 studies in Renal Insufficiency, Chronic with a site in Egypt, this one is the 8th largest by enrollment of the 44 interventional ones that give a count, is one of 9 that started in 2026, is one of 23 with no phase, and was the 63rd registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →23 of the 64 studies in Renal Insufficiency, Chronic with a site in Egypt are open now. Recruiting first, the newest first:
Badr University · Sites in Egypt
Ages 36–58
Future University in Egypt · Sites in Egypt
Ages 18+
Ace Cells Lab Limited · Sites in Egypt
Ages 18–80
Sohag University · Sites in Egypt
Ages 18+
Ain Shams University · Sites in Egypt
Ages 18+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 8 · Phase 4 8
First in 2013; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 64 across the 44 interventional studies, 110 across the 20 observational. Of the 29 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 64 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Fatma Hatem Mokhtar as lead sponsor.
Fatma Hatem Mokhtar has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
6 of the studies in Renal Insufficiency, Chronic with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07706582Beni-Suef UniversityManagement of Iron Deficiency Anemia in Hemodialysis Patients | 2026-12 |
| NCT03436368Nazmy Edward SeifContinuous Spinal Anesthesia in Renal Transplantation | 2026-12 |
| NCT03778944Nazmy Edward SeifEnhancing Renal Graft Function During Donor Anesthesia | 2026-12 |
| NCT07640919Sohag UniversityPatterns of Cardiac Arrhythmia in Patients With Chronic Kidney Disease | 2026-12-20 |
| NCT07235891Alexandria UniversityRetinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease | 2026-12-20 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies in Renal Insufficiency, Chronic with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to determine whether ultrasound guided ESP block at 2nd thoracic vertebrae is non inferior to ultrasound guided ICBN block as adjunct to supraclavicular brachial plexus block in achieving complete sensory blockade of the medial upper arm during AVF superficialization
Arteriovenous fistula (AVF) superficialization is an essential procedure for patients with end-stage renal disease . The supraclavicular brachial plexus block is commonly used for upper extremity surgeries .Because the ICBN originates from the T2 nerve root below the C5-T1 nerve roots comprising the brachial plexus, brachial plexus blocks are ideally supplemented with an ICBN infiltration block for medial upper arm coverage.The ICBB requires precise ultrasound guidance to target the ICBN, which is small and variably located, making it technically challenging and time-intensive.
ESP block at T2 level can provide broad coverage, ease of Performance, superficial injection and requiring less technical expertise compared to the ICBB .
The patients are randomly allocated into 2 groups :
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults scheduled for upper extremity surgeries under regional anesthesia.
Exclusion Criteria:
•Allergy to local anesthetics.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1. Position: patient supine with arm abducted. 2. Ultrasound setup: High frequency probe positioned at upper axillary region. 3. Technique: Needle will be advanced into subcutaneous tissue, in-plane to target intercostobrachial nerve near axillary artery. 4. Drug: 10 ml of 0.5% bupivacaine.
Procedure: Ultrasound Guided Intercostobrachial Nerve Block
1. Position: patient sitting or in lateral decubitus. 2. Ultrasound setup: High frequency linear transducer will be placed in a parasagittal 2-3 cm lateral to spinous process at T2 level, erector spinae muscles will be identified superficial to the tip of T2 transverse process, patient's skin anesthetized with 3 ml of 2 % lidocaine subcutaneously, the tip of the 22- gauge 80-mm block needle (Sonoplex, Pajunk Medical, Geisingen, Germany) needle will be placed into the facial plane on the deep (anterior) aspect of erector spinae muscle. location of needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process then 10 ml of 0.5% bupivacaine will be injected into the facial plane that will be confirmed by visible hydrodissection .
Procedure: Ultrasound Guided Erector Spinae Plane Block at T2 level
1. Position: patient supine with arm abducted. 2. Ultrasound setup: High frequency probe positioned at upper axillary region. 3. Technique: Needle will be advanced into subcutaneous tissue, in-plane to target intercostobrachial nerve near axillary artery. 4. Drug: 10 ml of 0.5% bupivacaine.
Also known as: ICBB
1. Position: patient sitting or in lateral decubitus. 2. Ultrasound setup: High frequency linear transducer will be placed in a parasagittal 2-3 cm lateral to spinous process at T2 level, erector spinae muscles will be identified superficial to the tip of T2 transverse process, patient's skin anesthetized with 3 ml of 2 % lidocaine subcutaneously, the tip of the 22- gauge 80-mm block needle(Sonoplex, Pajunk Medical, Geisingen, Germany) needle will be placed into the facial plane on the deep (anterior) aspect of erector spinae muscle. location of needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process then 10 ml of 0.5% bupivacaine will be injected into the facial plane that will be confirmed by visible hydrodissection .
Proportion of Participants Achieving complete sensory blockade within 30 minutes without conversion to general anesthesia, irrespective of rescue sedation.
Complete sensory blockade was assessed 30 minutes after completion of the block procedure. Success was defined as achievement of adequate sensory blockade without conversion to general anesthesia, irrespective of rescue sedation. The outcome was recorded as the number and proportion of participants meeting all success criteria in each treatment group.
Time frame: 30 minutes after completion of the block procedure
Time to achieve complete sensory blockade.
Time, in minutes, from completion of block placement to achievement of complete sensory blockade, as assessed by the study's sensory-testing procedure.
Time frame: From completion of block placement until complete sensory blockade is achieved, assessed up to 30 minutes.
Patient's satisfaction (assessed using Likert scale).
Patient satisfaction assessed using the 5-point Likert scale and the EVAN-LR perioperative satisfaction questionnaire, as specified in the study protocol. The scoring range, interpretation of higher scores, and whether both measures were analyzed separately should be explicitly stated.
Time frame: At 24 hours; the postoperative assessment.
Total opioid consumption in 24 hours
Total opioid consumption in 24 hours postoperative in mg /kg
Time frame: in the first 24 hours
The visual analog scale(VAS)
measure a patient pain intensty ,commonly used interpretation is 0:no pain,1-3 :mild pain.4-6:moderate pain,7-10 :sever pain
Time frame: in the first 12 hours
the proportion of participants achieving complete sensory blockade within 30 minutes, without discomfort requiring rescue sedation and without conversion to general anesthesia.
the proportion of participants achieving complete sensory blockade within 30 minutes, without discomfort requiring rescue sedation and without conversion to general anesthesia.
Time frame: 30 minutes after completion of the block procedure
Plan to share: Undecided
Ran from Jul 2026 to primary completion in Oct 2026, 2 months.
Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's 2 months is below that.
Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
Primary completion moved twice since we started tracking on Sep 25, 2026: Dec 2026 → Oct 2026, last on Oct 28, 2026.
Completion moved twice since we started tracking on Sep 25, 2026: Dec 2026 → Oct 2026, last on Oct 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →